Showing results (2611-2620 of 6,778) with videos related to

Sort By:
Pageof 678
Clinical Therapeutics|February 23, 2010
Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trialsSeyed-Moayed Alavian, Seyed-Vahid Tabatabaei
Clinical Therapeutics|February 23, 2010
Irreversible encephalopathy after treatment with high-dose intravenous metronidazoleMiriam V R Groothoff, Jannette Hofmeijer, Maaike A Sikma, et al.
Clinical Therapeutics|February 23, 2010
Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority studyGavin R Graff, Karen Maguiness, John McNamara, et al.
Clinical Therapeutics|February 23, 2010
Results of a retrospective database analysis of drug utilization and costs for treatment of chronic hepatitis B virus infection in the northern Netherlands between 2000 and 2006Hong Anh T Tu, Jens H J Bos, Herman J Woerdenbag, et al.
Clinical Therapeutics|February 23, 2010
Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover studyGuillermo Di Girolamo, Paola Czerniuk, Roberto Bertuola, et al.
Clinical Therapeutics|October 22, 2009
Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and childrenMark B Abelson, Gail L Torkildsen, Jon I Williams, et al.
Clinical Therapeutics|May 1, 1997
Effect of doxazosin therapy on glucose tolerance and lipid metabolism in hypertensive patients with impaired glucose toleranceH Shionoiri, K Ashino, K Yamanaka, et al.
Clinical Therapeutics|May 1, 1997
Cost-effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed-care organizationM E Spearman, K Summers, V Moore, et al.
Clinical Therapeutics|January 1, 1993
Effect of lansoprazole on Helicobacter pyloriH Lamouliatte
Clinical Therapeutics|January 1, 1994
Predictors of medication noncompliance in a sample of older adultsS J Coons, S L Sheahan, S S Martin, et al.
Pageof 678